欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2014, Vol. 19 ›› Issue (12): 1337-1341.

• 基础研究 • 上一篇    下一篇

乙酰半胱氨酸镁盐-甘草酸环状样二聚体治疗大鼠肝纤维化的实验研究

庄让笑1, 王福根1, 邵益丹1, 方红英1, 孙晶晶1, 席建军1, 潘金明1, 梁伟峰2, 刘寿荣1   

  1. 1浙江中医药大学附属西溪医院,杭州 310023,浙江;
    2浙江大学医学院附属第一医院,杭州 310003,浙江
  • 收稿日期:2014-07-11 修回日期:2014-08-26 发布日期:2020-07-20
  • 通讯作者: 刘寿荣,通信作者,男,教授,主任医师,研究方向:从事传染病、肝病的基础研究和治疗。Tel:0571-85463955 E-mail:lsr85463990@sina.com
  • 作者简介:庄让笑,男,主任药师,研究方向:肝炎药物的研究。Tel:0571-85463955 E-mail:zhuangrangxiao@sina
  • 基金资助:
    浙江省自然科学基金项目(Y2101449);杭州市科技发展计划项目(20100733Q13)

Experimental study of acetylcysteine magnesium-glycyrrhizin fine antipode dimers on rat liver fibrosis

ZHUANG Rang-xiao1, WANG Fu-gen1, SHAO Yi-dan1, FANG Hong-ying1, SUN Jing-jing1, XI Jian-jun1, PAN Jin-ming1, LIANG Wei-feng2, LIU Shou-rong1   

  1. 1Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou 310023, Zhejiang, China;
    2the First Affiliated Hospital of Zhejiang University Medical College, Hangzhou 310010, Zhejiang, China
  • Received:2014-07-11 Revised:2014-08-26 Published:2020-07-20

摘要: 目的: 研究新合成产物乙酰半胱氨酸镁盐-甘草酸环状样二聚体(acetylcysteine magnesium-glycyrrhizin fine antipode dimers,GFA-NAC·Mg)治疗大鼠肝纤维化的效果。方法: 25%四氯化碳(CCl4)制备大鼠肝纤维化模型,GFA-NAC·Mg按25、50、100 mg/kg 剂量每日分别腹腔注射进行肝纤维化治疗,给药8周后处死大鼠,用肝纤维化网格染色观察肝纤维化情况,ELISA法测定血清羟脯氨酸(Hyp)和肝组织丙二醛(MDA)、超氧化物歧化酶(SOD)、转化生长因子-β1 (TGF-β1)、血小板衍生生长因子(PDGF)。结果: 大鼠肝组织病理结果显示其肝纤维化处于Ⅲ-Ⅳ期;与模型组比较,GFA-NAC·Mg治疗后血清Hyp明显降低;肝组织抗氧化指标SOD显著升高,MDA明显下降;肝纤维化指标TGF-β1、PDGF在组织含量下降;GFA-NAC·Mg各组网格染色显示肝纤维化好转。结论: GFA-NAC·Mg对肝纤维化大鼠有较好实验治疗作用,可能通过抑制PDGF和TGF-β1的表达而实现。

关键词: 乙酰半胱氨酸镁盐-甘草酸环状样二聚体, 肝纤维化, 血小板衍生生长因子, 转化生长因子-β1

Abstract: AIM: To investigate efficacy of GFA-NAC·Mg on rat liver fibrosis. METHODS: Preparation of liver fibrosis model in rats with 25% carbontetrachloride (CCl4) by subcutaneous injection,GFA-NAC·Mg intraperitoneal injected treating liver fibrosis with 25,50 and 100 mg/kg. All the rats were killed after 8 weeks of administration with grid staining and the levels of Hyp in serum were detected with ELISA assay,the contents of the MDA,SOD,TGF-β1,PDGF for liver fibrosis and liver tissue were tested. RESULTS: The liver tissue of fibrosis showed stage Ⅲ-Ⅳ.Compared with the model group,the serum of Hyp significantly was reduced after GFA-NAC·Mg treatment.The antioxidant index SOD significantly was increased in liver tissue while MDA was decreased.Liver fibrosis markers TGF-β1 and PDGF content were decreased. Liver fibrosis was improved after GFA-NAC·Mg treatment in each groups by grid staining. CONCLUSION: GFA-NAC·Mg has a better therapeutic effect on rat liver fibrosis by inhibiting the expression of PDGF and TGF-β1.

Key words: acetylcysteine magnesium-glycyrrhizin fine antipode dimmers, liver fibrosis, platelet derived growth factor(PDGF), transforming growth factor beta1(TGF-β1)

中图分类号: